Committed to providing comprehensive support for global drug development

The CD38 gene is located on human chromosome 4 (4p15.32) and encodes a type II transmembrane glycoprotein with an approximate molecular weight of 45 kDa. This protein consists of an intracellular short peptide segment, a transmembrane helical domain, and an extracellular catalytic region, possessing unique bifunctional enzymatic activity. It can generate cyclic ADP-ribose (cADPR) and other second messengers using nicotinamide adenine dinucleotide (NAD+) as a substrate, thereby regulating intracellular calcium mobilization. Additionally, it can hydrolyze cADPR to participate in nucleotide metabolic homeostasis. CD38 is widely expressed in the immune system (such as B cells, T cells, NK cells, and monocytes) and non-hematopoietic tissues (such as the heart and pancreas), where it plays a central role in cell activation, proliferation, and signal transduction.

  
In pathological conditions, CD38 has emerged as a key target for various diseases. In the field of hematological malignancies, it is highly expressed on the surface of multiple myeloma cells (positive in 80%-100% of patients with plasma cell myeloma), chronic lymphocytic leukemia, and mantle cell lymphoma cells, and its expression level is negatively correlated with prognosis. Anti-CD38 monoclonal antibody drugs (such as daratumumab and isatuximab) significantly improve the survival of patients with relapsed and refractory multiple myeloma through mechanisms including complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and direct induction of apoptosis.

The CD38 knockout NFAT-Luc Jurkat cell reporter gene drug target model reflects the activation level of the T cell receptor (TCR) signaling pathway through the signal of the reporter gene. The principle is shown in the figure below.

Figure 1. CD38 Knockout NFAT-Luc Jurkat Cell Model.

  Figure 2. CD38 Knockout NFAT-Luc Jurkat Cells, which are NFAT-Luc Jurkat Cells with human CD38 knocked out.

Figure 3. Sanger of CD38 KO NFAT-Luc Jurkat Cell.

Figure 4. Dose Response of CD38 & CD3E Bispecific Antibody in CD38 KO NFAT-Luc Jurkat(C8) with or without Daudi(CD38+).

Cell Passage Procedures

1.This cell line grows in suspension.
2.Upon receipt, cells should be thawed immediately or stored in liquid nitrogen until use.
3.Before thawing, pre-warm the water bath and culture medium to 37 °C, and prepare a small amount of dry ice.
4.Remove the cryovial from storage and transport it to the cell culture laboratory on dry ice.
5.Rapidly thaw the cells in a 37 °C water bath. Once the cells are completely thawed, spray the cryovial with 70% ethanol for disinfection and transfer it to a biosafety cabinet.
6.Add 10 mL of pre-warmed culture medium into a 15 mL centrifuge tube. Transfer the contents of the cryovial into the tube and centrifuge at 1000 rpm for 5 minutes.
7.Carefully discard the supernatant. Resuspend the cell pellet in 5 mL of pre-warmed culture medium by gentle pipetting. Immediately perform cell counting and adjust the cell density to 3–6 × 10⁵ cells/mL based on the counting results, then transfer the cells into a culture flask.
8.Count the cells every 1–2 days. When the cell density exceeds 1 × 10⁶ cells/mL, passage the cells promptly or add fresh culture medium. Maintain the cell density between 2 × 10⁵ and 1 × 10⁶ cells/mL.

Suspension Cell Cryopreservation Procedure:

1.Collect 8 × 10⁶ cells, centrifuge, and discard the supernatant.
2.Add 1 mL of cell freezing medium (90% FBS + 10% DMSO) and gently pipette to mix thoroughly. Transfer the suspension into a cryovial.
3.Immediately place the cryovial into a controlled-rate freezing container (Nalgene 5100-0001), fill with isopropanol up to the indicated level, and store at −80 °C.
4.After 24 hours, transfer the cryovial to liquid nitrogen for long-term storage.